Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:APLIFNASDAQ:BLRXNASDAQ:ERNANASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLIFAppili Therapeutics$0.02-5.8%$0.02$0.01▼$0.04$2.56M-0.5482,613 shs1,000 shsBLRXBioLineRx$3.22+7.3%$3.10$2.30▼$35.60$10.72M1.3166,643 shs34,555 shsERNAEterna Therapeutics$0.22+5.4%$0.24$0.15▼$2.63$11.29M4.792.80 million shs210,780 shsPHIOPhio Pharmaceuticals$2.04-8.5%$1.58$0.97▼$9.79$9.75M1.092.33 million shs444,284 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLIFAppili Therapeutics-5.80%-14.92%-24.91%-11.34%-24.37%BLRXBioLineRx+7.33%+11.81%+1.58%-26.35%-86.87%ERNAEterna Therapeutics+5.42%+16.76%-5.96%-61.84%-87.59%PHIOPhio Pharmaceuticals-8.52%-25.27%+56.92%-7.69%-66.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLIFAppili Therapeutics0.4087 of 5 stars0.03.00.00.02.20.80.0BLRXBioLineRx2.2304 of 5 stars3.33.00.00.02.70.01.3ERNAEterna Therapeutics1.5634 of 5 stars0.05.00.00.02.71.70.6PHIOPhio Pharmaceuticals2.6212 of 5 stars3.52.00.00.03.50.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLIFAppili Therapeutics 0.00N/AN/AN/ABLRXBioLineRx 2.50Moderate Buy$26.00707.45% UpsideERNAEterna Therapeutics 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$4.0096.08% UpsideCurrent Analyst Ratings BreakdownLatest APLIF, PHIO, ERNA, and BLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/2/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/31/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $26.002/19/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLIFAppili Therapeutics$630K4.06N/AN/A($0.05) per share-0.42BLRXBioLineRx$28.94M0.37N/AN/A$7.30 per share0.44ERNAEterna Therapeutics$582K19.39N/AN/A$0.41 per share0.53PHIOPhio PharmaceuticalsN/AN/AN/AN/A$18.57 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLIFAppili Therapeutics-$2.80M-$0.02N/A∞N/AN/AN/A-209.09%N/ABLRXBioLineRx-$60.61M-$8.80N/AN/AN/A-90.57%-163.37%-34.21%5/27/2025 (Estimated)ERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%5/13/2025 (Estimated)PHIOPhio Pharmaceuticals-$10.83M-$10.92N/A0.54N/AN/A-134.57%-108.39%5/8/2025 (Estimated)Latest APLIF, PHIO, ERNA, and BLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025N/APHIOPhio Pharmaceuticals-$1.23N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLIFAppili TherapeuticsN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/AERNAEterna TherapeuticsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLIFAppili TherapeuticsN/A0.110.11BLRXBioLineRx2.111.521.37ERNAEterna TherapeuticsN/A0.480.48PHIOPhio PharmaceuticalsN/A6.386.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLIFAppili TherapeuticsN/ABLRXBioLineRx1.56%ERNAEterna Therapeutics70.55%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipAPLIFAppili Therapeutics11.84%BLRXBioLineRx1.10%ERNAEterna Therapeutics4.49%PHIOPhio Pharmaceuticals0.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLIFAppili Therapeutics8121.27 million106.91 millionNot OptionableBLRXBioLineRx403.33 million3.29 millionOptionableERNAEterna Therapeutics1052.25 million5.17 millionNo DataPHIOPhio Pharmaceuticals104.78 million6.85 millionNot OptionableAPLIF, PHIO, ERNA, and BLRX HeadlinesRecent News About These CompaniesBest Momentum Stocks to Buy for April 23rdApril 23 at 11:15 AM | zacks.comBest Value Stocks to Buy for April 23rdApril 23 at 7:46 AM | zacks.comPhio Pharmaceuticals Corp. Common StockApril 12, 2025 | fxempire.comPhio Pharmaceuticals announces Safety Monitoring Committee recommendation to advance INTASYL PH-762 skin cancer studyApril 12, 2025 | pharmabiz.comPhio advances skin cancer treatment with successful trialApril 11, 2025 | uk.investing.comPHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next DoseApril 10, 2025 | zacks.comThis Biotech Is Ripping Following Phase 1b Trial AnnouncementApril 9, 2025 | msn.comPhio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s ThrilledApril 9, 2025 | msn.comPhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation CohortApril 9, 2025 | newsfilecorp.comAnalysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Phio Pharmaceuticals (PHIO)April 8, 2025 | markets.businessinsider.comPhio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894April 3, 2025 | newsfilecorp.comPhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business UpdateMarch 31, 2025 | newsfilecorp.comAmerican Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual MeetingMarch 10, 2025 | newsfilecorp.comPhio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation StudyMarch 5, 2025 | newsfilecorp.comPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesFebruary 26, 2025 | newsfilecorp.comPhio Pharmaceuticals expands board with new directorFebruary 22, 2025 | investing.comPhio Pharmaceuticals Appoints David Deming to BoardFebruary 20, 2025 | tipranks.comPhio Pharmaceuticals Announces Appointment of David H. Deming to Board of DirectorsFebruary 20, 2025 | newsfilecorp.comPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesFebruary 3, 2025 | newsfilecorp.comPhio Pharmaceuticals Corp (PHIO) Stock Trading RecapJanuary 31, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTop 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing Market2 Penny Stocks With $10 Potential By Thomas Hughes | April 16, 2025View 2 Penny Stocks With $10 Potential 2 Reasons to Buy Apple Stock and 1 Significant RiskBy Chris Markoch | April 2, 2025View 2 Reasons to Buy Apple Stock and 1 Significant RiskBig Blue's Big Shift: IBM's Turnaround Bet on Cloud and AIBy Jeffrey Neal Johnson | April 7, 2025View Big Blue's Big Shift: IBM's Turnaround Bet on Cloud and AI2 Strong Utilities Plays With Booming Earnings and Room to GrowBy Nathan Reiff | April 24, 2025View 2 Strong Utilities Plays With Booming Earnings and Room to GrowAPLIF, PHIO, ERNA, and BLRX Company DescriptionsAppili Therapeutics OTCMKTS:APLIF$0.02 0.00 (-5.80%) As of 04/25/2025 11:32 AM EasternAppili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.BioLineRx NASDAQ:BLRX$3.22 +0.22 (+7.33%) Closing price 04/25/2025 03:56 PM EasternExtended Trading$3.28 +0.06 (+1.86%) As of 04/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Eterna Therapeutics NASDAQ:ERNA$0.22 +0.01 (+5.42%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$0.21 -0.01 (-3.70%) As of 04/25/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Phio Pharmaceuticals NASDAQ:PHIO$2.04 -0.19 (-8.52%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.08 +0.04 (+1.96%) As of 04/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
